Hanmi Pharmaceutical stock jumps 11% on $1.4 billion Eli Lilly tech export deal

Hanmi Pharmaceutical's stock experienced a significant boost, climbing over 11% in early trading on the back of a major technology export deal. The surge reflects investor confidence following the announcement of a 1.9 trillion won (approximately $1.4 billion) technology transfer agreement with U.S. pharmaceutical leader Eli Lilly.

The agreement centers on Hanmi Pharmaceutical's innovative drug pipeline, marking a substantial validation of the company's research and development capabilities. The deal is expected to provide a significant financial injection and enhance the global reach of Hanmi's therapeutic candidates.

This collaboration underscores the growing trend of global pharmaceutical companies seeking external innovation to bolster their portfolios. For Hanmi Pharmaceutical, the partnership represents a critical step in monetizing its R&D efforts and solidifying its position in the competitive biopharmaceutical landscape.